HIV infection and risk, prevention, and testing behaviors among injecting drug users -- National HIV Behavioral Surveillance System, 20 U.S. cities, 2009.

PROBLEM/CONDITION At the end of 2009, an estimated 1,148,200 persons aged ≥13 years were living with human immunodeficiency virus (HIV) infection in the United States. Despite the recent decreases in HIV infection attributed to injection drug use, 8% of new HIV infections in 2010 occurred among injecting drug users (IDUs). REPORTING PERIOD June-December 2009. DESCRIPTION OF SYSTEM The National HIV Behavioral Surveillance System (NHBS) collects HIV prevalence and risk behavior data in selected metropolitan statistical areas (MSAs) from three populations at high risk for HIV infection: men who have sex with men, IDUs, and heterosexual adults at increased risk for HIV infection. Data for NHBS are collected in rotating cycles. For the 2009 NHBS cycle, IDUs were recruited in 20 participating MSAs using respondent-driven sampling, a peer-referral sampling method. Participants were eligible if they were aged ≥18 years, lived in a participating MSA, were able to complete a behavioral survey in English or Spanish, and reported that they had injected drugs during the past 12 months. Consenting participants completed an interviewer-administered (face-to-face), anonymous standardized questionnaire about HIV-associated behaviors, and all participants were offered anonymous HIV testing. Analysis of 2009 NHBS data represents the first large assessment of HIV prevalence among IDUs in the United States in >10 years. RESULTS This report summarizes two separate analyses using unweighted data from 10,200 eligible IDUs in 20 MSAs from the second collection cycle of NHBS in 2009. Both an HIV infection analysis and a behavioral analysis were conducted. Different denominators were used in each analysis because of the order and type of exclusion criteria applied. For the HIV infection analysis, of the 10,200 eligible participants, 10,090 had a valid HIV test result, of whom 906 (9%) tested positive for HIV (range: 2%-19% by MSA). When 509 participants who reported receiving a previous positive HIV test result were excluded from this analysis, 4% (397 of 9,581 participants) tested HIV-positive. For the behavioral analysis, because knowledge of HIV status might influence risk behaviors, 548 participants who reported a previous HIV-positive test result were excluded from the 10,200 eligible participants. All subsequent analyses were conducted for the remaining 9,652 participants. The most commonly injected drugs during the past 12 months among these participants were heroin (90%), speedball (heroin and cocaine combined) (58%), and cocaine or crack (49%). Large percentages of participants reported receptive sharing of syringes (35%); receptive sharing of other injection equipment, such as cookers, cotton, or water (58%); and receptive sharing of syringes to divide drugs (35%). Many participants reported having unprotected sex with opposite-sex partners during the past 12 months: 70% of men and 73% of women had unprotected vaginal sex, and 25% of men and 21% of women had unprotected anal sex. A combination of unsafe injection- and sex-related behaviors during the past 12 months was commonly reported; 41% of participants who reported unprotected vaginal sex with one or more opposite-sex partners, and 53% of participants who reported unprotected anal sex with one or more opposite-sex partners also reported receptive sharing of syringes. More women than men reported having sex in exchange for money or drugs (31% and 18%, respectively). Among men, 10% had oral or anal sex with one or more male partners during the past 12 months. Many participants (74%) reported noninjection drug use during the past 12 months, and 41% reported binge drinking during the past 30 days. A large percentage of participants (74%) had ever been tested for hepatitis C, 41% had received a hepatitis C virus infection diagnosis, and 29% had received a vaccination against hepatitis A virus, hepatitis B virus, or both. Most (88%) had been tested for HIV during their lifetime, and 49% had been tested during the past 12 months. Approximately half of participants received free HIV prevention materials during the past 12 months, including condoms (50%) and sterile syringes (44%) and other injection equipment (41%). One third of participants had been in an alcohol or a drug treatment program, and 21% had participated in an individual- or a group-level HIV behavioral intervention. INTERPRETATION IDUs in the United States continue to engage in sexual and drug-use behaviors that increase their risk for HIV infection. The large percentage of participants in this study who reported engaging in both unprotected sex and receptive sharing of syringes supports the need for HIV prevention programs to address both injection and sex-related risk behaviors among IDUs. Although most participants had been tested for HIV infection previously, less than half had been tested in the past year as recommended by CDC. In addition, many participants had not been vaccinated against hepatitis A and B as recommended by CDC. Although all participants had injected drugs during the past year, only a small percentage had recently participated in an alcohol or a drug treatment program or in a behavioral intervention, suggesting an unmet need for drug treatment and HIV prevention services. PUBLIC HEALTH ACTION To reduce the number of HIV infections among IDUs, additional efforts are needed to decrease the number of persons who engage in behaviors that increase their risk for HIV infection and to increase their access to HIV testing, alcohol and drug treatment, and other HIV prevention programs. The National HIV/AIDS Strategy for the United States delineates a coordinated response to reduce HIV incidence and HIV-related health disparities among IDUs and other disproportionately affected groups. CDC's high-impact HIV prevention approach provides an essential step toward achieving these goals by using combinations of scientifically proven, cost-effective, and scalable interventions among populations at greatest risk. NHBS data can be used to monitor progress toward the national strategy goals and to guide national and local planning efforts to maximize the impact of HIV prevention programs.

[1]  W. Latimer,et al.  Factors related to correctional facility incarceration among active injection drug users in Baltimore, MD. , 2008, Drug and alcohol dependence.

[2]  R. Garfein,et al.  Self-Reported Hepatitis C Virus Antibody Status and Risk Behavior in Young Injectors , 2006, Public health reports.

[3]  A. Wasley,et al.  Surveillance for acute viral hepatitis - United States, 2007. , 2009, Morbidity and mortality weekly report. Surveillance summaries.

[4]  J. Rich,et al.  Opportunities to Diagnose, Treat, and Prevent HIV in the Criminal Justice System , 2010, Journal of acquired immune deficiency syndromes.

[5]  N. Crepaz,et al.  Higher incidence of clear cell adenocarcinoma of the cervix and vagina among women born between 1947 and 1971 in the United States , 2011, Cancer Causes & Control.

[6]  R. Curtis,et al.  Syringe-mediated drug sharing among injecting drug users: patterns, social context and implications for transmission of blood-borne pathogens. , 1996, Social science & medicine.

[7]  A. Lansky,et al.  Developing an HIV Behavioral Surveillance System for Injecting Drug Users: The National HIV Behavioral Surveillance System , 2007, Public health reports.

[8]  R. Garfein,et al.  Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. , 2002, American journal of epidemiology.

[9]  Richard J. Block,et al.  3 – PART A , 1960 .

[10]  A. Lansky,et al.  Estimated Percentages and Characteristics of Men Who Have Sex with Men and Use Injection Drugs — United States, 1999–2011 , 2013, MMWR. Morbidity and mortality weekly report.

[11]  H. Margolis,et al.  Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease , 1998 .

[12]  H. Hagan,et al.  Attribution of hepatitis C virus seroconversion risk in young injection drug users in 5 US cities. , 2010, The Journal of infectious diseases.

[13]  L. Thorpe,et al.  Hepatitis C virus infection: prevalence, risk factors, and prevention opportunities among young injection drug users in Chicago, 1997-1999. , 2000, The Journal of infectious diseases.

[14]  T. Heeren,et al.  Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  R. Garfein,et al.  Update and Overview of Practical Epidemiologic Aspects of HIV/AIDS among Injection Drug Users in the United States , 2006, Journal of Urban Health.

[16]  Nicole Crepaz,et al.  Best-evidence interventions: findings from a systematic review of HIV behavioral interventions for US populations at high risk, 2000-2004. , 2007, American journal of public health.

[17]  H. Gayle,et al.  HIV Prevalence Trends in Selected Populations in the United States Results from National Serosurveillance , 1993 – 1997 , 2001 .

[18]  D. Fleming,et al.  From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. , 1999, Sexually transmitted infections.

[19]  J. Watters,et al.  HIV seroprevalence among street-recruited injection drug and crack cocaine users in 16 US municipalities. , 1998, American journal of public health.

[20]  M. Stein,et al.  Alcohol and HIV risk taking among intravenous drug users. , 2002, Addictive Behaviours.

[21]  P. Shapshak,et al.  Detection of HIV-1 in injection paraphernalia: risk in an era of heightened awareness. , 2006, AIDS patient care and STDs.

[22]  T. S. Jones,et al.  HIV risk behaviors associated with the injection process: multiperson use of drug injection equipment and paraphernalia in injection drug user networks. , 1998, Substance use & misuse.

[23]  A. Lansky,et al.  The Role of Formative Research in the National HIV Behavioral Surveillance System , 2009, Public health reports.

[24]  M. Abrahamowicz,et al.  American Journal of Epidemiology Original Contribution Trends in Human Immunodeficiency Virus Incidence and Risk Behavior among Injection Drug Users in Montreal, Canada: a 16-year Longitudinal Study , 2022 .

[25]  Gary Marks,et al.  Meta-Analysis of High-Risk Sexual Behavior in Persons Aware and Unaware They are Infected With HIV in the United States: Implications for HIV Prevention Programs , 2005, Journal of acquired immune deficiency syndromes.

[26]  J. Boivin,et al.  Risk of hepatitis C virus transmission through drug preparation equipment: a systematic and methodological review , 2008, Journal of Viral Hepatitis.

[27]  T. Patterson,et al.  Characteristics of Female Sex Workers With US Clients in Two Mexico-US Border Cities , 2008, Sexually transmitted diseases.

[28]  D. D. Des Jarlais,et al.  Hepatitis C Virus Infection Among Injection Drug Users: Survival Analysis of Time to Seroconversion , 2004, Epidemiology.

[29]  Atlanta,et al.  Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. , 2006, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[30]  P. Friedmann,et al.  Alcohol use and sexual risk taking among hazardously drinking drug injectors who attend needle exchange. , 2001, Alcoholism, clinical and experimental research.

[31]  P. Bacchetti,et al.  Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: risk-factor analysis , 2001, The Lancet.

[32]  D. D. Des Jarlais,et al.  Behavior Change and Health-Related Interventions for Heterosexual Risk Reduction Among Drug Users , 2006, Substance use & misuse.

[33]  D. D. Des Jarlais,et al.  HIV prevention for injecting drug users: the first 25 years and counting. , 2008, Psychosomatic medicine.

[34]  D. Vlahov,et al.  Prevalence, incidence, and correlates of chlamydia and gonorrhea among young adult injection drug users. , 2001, Journal of substance abuse.

[35]  A. Lansky,et al.  Piloting a System for Behavioral Surveillance Among Heterosexuals at Increased Risk of HIV in the United States , 2012, The open AIDS journal.

[36]  A. Baker,et al.  Characteristics and harms associated with injecting versus smoking methamphetamine among methamphetamine treatment entrants. , 2008, Drug and alcohol review.

[37]  R. Garfein,et al.  Young adult injection drug users in the United States continue to practice HIV risk behaviors. , 2009, Drug and alcohol dependence.

[38]  M. Alter,et al.  The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002 , 2006, Annals of Internal Medicine.

[39]  E. Hudes,et al.  Effectiveness of Brief Counseling in Reducing HIV Risk Behavior in Injecting Drug Users: Final Results of Randomized Trials of Counseling with and Without HIV Testing , 1999, AIDS and Behavior.

[40]  E. Vittinghoff,et al.  Risk behaviors after hepatitis C virus seroconversion in young injection drug users in San Francisco. , 2009, Drug and alcohol dependence.

[41]  R. Allard,et al.  Access to Sterile Injecting Equipment is More Important Than Awareness of HCV Status for Injection Risk Behaviors Among Drug Users , 2009, Substance use & misuse.

[42]  M. McFarlane,et al.  CDC Consultation on Methamphetamine Use and Sexual Risk Behavior for HIV/STD Infection: Summary and Suggestions , 2006, Public health reports.

[43]  D. Vlahov,et al.  Sex differences in risk factors for hiv seroconversion among injection drug users: a 10-year perspective. , 2001, Archives of internal medicine.

[44]  D. Metzger,et al.  Drug Treatment as HIV Prevention: Expanding Treatment Options , 2010, Current HIV/AIDS reports.

[45]  Patricia E. Penn,et al.  Injection behaviors among injection drug users in treatment: the role of hepatitis C awareness. , 2012, Addictive Behaviours.

[46]  A. Estrada Health disparities among African-American and Hispanic drug injectors--HIV, AIDS, hepatitis B virus and hepatitis C virus: a review. , 2005, AIDS.

[47]  M. Ross,et al.  Prevalence of sexually transmitted infections and associated risk factors among populations of drug abusers. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[48]  J. Hahn,et al.  Hepatitis C virus risk behaviors within the partnerships of young injecting drug users. , 2010, Addiction.

[49]  P. Williams,et al.  Setting targets for universal access to HIV prevention, treatment and care for injecting drug users (IDUs): towards consensus and improved guidance. , 2008, The International journal on drug policy.

[50]  J. Montaner,et al.  Incarceration experiences in a cohort of active injection drug users. , 2008, Drug and alcohol review.

[51]  Susan G. Sherman,et al.  The role of sexual transmission of HIV infection among injection and non-injection drug users , 2003, Journal of Urban Health.

[52]  Stuart Berman,et al.  Sexually transmitted diseases treatment guidelines, 2010. , 2010, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[53]  J. Prejean,et al.  Cases of HIV infection and AIDS in the United States and dependent areas, 2007 , 2007 .

[54]  G. Burstein,et al.  Sexually transmitted diseases treatment guidelines , 2003, Current opinion in pediatrics.

[55]  M. Stein,et al.  Adherence to Antiretroviral Therapy Among HIV-Infected Methadone Patients: Effect of Ongoing Illicit Drug Use* , 2000, The American journal of drug and alcohol abuse.

[56]  P. Kerndt,et al.  Predictors of syphilis seroreactivity and prevalence of HIV among street recruited injection drug users in Los Angeles County, 1994–6 , 2000, Sexually transmitted infections.

[57]  S. Martins,et al.  Correlates of risky injection practices among past-year injection drug users among the US general population. , 2011, Drug and alcohol dependence.

[58]  Rebecca L Morgan,et al.  Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. , 2012, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[59]  Yuanan Lu,et al.  Hepatitis C virus infection in patients with HIV-1: epidemiology, natural history and management , 2014, Expert review of gastroenterology & hepatology.

[60]  W. Hall,et al.  Levels and correlates of polydrug use among heroin users and regular amphetamine users. , 1995, Drug and alcohol dependence.

[61]  T. Patterson,et al.  Polydrug Use among IDUs in Tijuana, Mexico: Correlates of Methamphetamine Use and Route of Administration by Gender , 2009, Journal of Urban Health.

[62]  Inda,et al.  The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. , 1999, The New England journal of medicine.

[63]  Robert T. Chen,et al.  Estimating the Number of Persons Who Inject Drugs in the United States by Meta-Analysis to Calculate National Rates of HIV and Hepatitis C Virus Infections , 2014, PloS one.

[64]  J. Inciardi,et al.  HIV, HBV, and HCV Infections Among Drug-Involved, Inner-City, Street Sex Workers in Miami, Florida , 2006, AIDS and Behavior.

[65]  D. D. Des Jarlais,et al.  HIV infection among people who inject drugs: the challenge of racial/ethnic disparities. , 2013, The American psychologist.

[66]  D. Vlahov,et al.  Correlates of HIV infection among young adult short-term injection drug users , 2000, AIDS.

[67]  M. Sulkowski,et al.  Viral hepatitis and HIV coinfection. , 2008, Journal of hepatology.

[68]  Patrick S Sullivan,et al.  Behavioral Surveillance among People at Risk for HIV Infection in the U.S.: The National HIV Behavioral Surveillance System , 2007, Public health reports.

[69]  D. Vlahov,et al.  Progress in HIV Reduction and Prevention Among Injection and Noninjection Drug Users , 2010, Journal of acquired immune deficiency syndromes.

[70]  R. Booth,et al.  Sex related HIV risk behaviors: differential risks among injection drug users, crack smokers, and injection drug users who smoke crack. , 2000, Drug and alcohol dependence.